These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30789450)

  • 1. The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.
    Abulizi X; Ribaudo HJ; Flandre P
    J Acquir Immune Defic Syndr; 2019 May; 81(1):44-51. PubMed ID: 30789450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials.
    Abulizi X; Flandre P
    J Clin Epidemiol; 2018 Apr; 96():63-72. PubMed ID: 29289760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
    Huang B; Kuan PF
    Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
    Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
    JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.
    Trinquart L; Jacot J; Conner SC; Porcher R
    J Clin Oncol; 2016 May; 34(15):1813-9. PubMed ID: 26884584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.
    Kloecker DE; Davies MJ; Khunti K; Zaccardi F
    Ann Intern Med; 2020 Apr; 172(8):541-552. PubMed ID: 32203984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic RMST curves for survival analysis in clinical trials.
    Liao JJZ; Liu GF; Wu WC
    BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of restricted mean survival time in clinical follow-up study].
    Yang ZJ; Lyu JJ; Hou YW; Chen Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):247-250. PubMed ID: 30744281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data.
    Huang Q; Tian C
    Comput Math Methods Med; 2022; 2022():7264382. PubMed ID: 36619796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjusting for covariates in analysis based on restricted mean survival times.
    Zhong Y; Zhao O; Zhang B; Yao B
    Pharm Stat; 2022 Jan; 21(1):38-54. PubMed ID: 34231308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.
    Liang F; Zhang S; Wang Q; Li W
    Ann Oncol; 2018 May; 29(5):1320-1324. PubMed ID: 29788167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug use.
    Calkins KL; Canan CE; Moore RD; Lesko CR; Lau B
    BMC Med Res Methodol; 2018 Mar; 18(1):27. PubMed ID: 29523081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint.
    Rulli E; Ghilotti F; Biagioli E; Porcu L; Marabese M; D'Incalci M; Bellocco R; Torri V
    Br J Cancer; 2018 Dec; 119(12):1456-1463. PubMed ID: 30420618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restricted mean survival time as a summary measure of time-to-event outcome.
    Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
    Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
    Weir IR; Trinquart L
    Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation.
    Perego C; Sbolli M; Specchia C; Fiuzat M; McCaw ZR; Metra M; Oriecuia C; Peveri G; Wei LJ; O'Connor CM; Psotka MA
    JACC Heart Fail; 2020 Dec; 8(12):973-983. PubMed ID: 33039446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.
    Monnickendam G; Zhu M; McKendrick J; Su Y
    Value Health; 2019 Apr; 22(4):431-438. PubMed ID: 30975394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group.
    Everest L; Blommaert S; Tu D; Pater JL; Hay A; Cheung MC; Chan KKW
    Value Health; 2022 Jul; 25(7):1157-1164. PubMed ID: 35779942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
    Pang H; Yang G; Ho JC; Leung TH; Shi Q; Hu C; Stinchcombe TE; Wang X
    Chin Clin Oncol; 2022 Feb; 11(1):7. PubMed ID: 35255696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the restricted mean survival time curve in survival analysis.
    Zhao L; Claggett B; Tian L; Uno H; Pfeffer MA; Solomon SD; Trippa L; Wei LJ
    Biometrics; 2016 Mar; 72(1):215-21. PubMed ID: 26302239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.